Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02313883 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Study to Evaluate the Safety and Efficacy of PerioSept® as Adjunct to SRP in Subjects With Periodontitis
A Phase 1 study, sponsored by Geistlich Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 127
- Enrollment target
NCT02313883 is a Phase 1 study that has completed, run by Geistlich Pharma. The registered enrollment target is 127 participants.
The verdict
NCT02313883, a Phase 1 study, has completed, sponsored by Geistlich Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 127 participants
- Enrollment target
Study Summary
A Pharmacokinetic Pilot followed by a Phase I/II, Blinded, Randomized, Controlled, Parallel Arm Trial to Evaluate the Safety, Tolerability and Efficacy of PerioSept® and Scaling and Root Planing in Subjects with Periodontitis
Interventions
- DRUG PerioSept(r)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2015-07 |
| Est. Completion | 2018-07-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02313883
The ClinicalTrials.gov registry entry for NCT02313883 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Geistlich Pharma, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PerioSept(r) is the first listed.
NCT02313883 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02313883 about?
NCT02313883 is a clinical study titled "A Phase I/II Study to Evaluate the Safety and Efficacy of PerioSept® as Adjunct to SRP in Subjects With Periodontitis". A Pharmacokinetic Pilot followed by a Phase I/II, Blinded, Randomized, Controlled, Parallel Arm Trial to Evaluate the Safety, Tolerability and Efficacy of PerioSept® and Scaling and Root Planing in Subjects with Periodontitis
What is the current status of trial NCT02313883?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 127 participants. The study started on 2015-07. Estimated completion is 2018-07-02.
What interventions are being tested in trial NCT02313883?
The interventions under investigation include: PerioSept(r) (DRUG).
Who is sponsoring clinical trial NCT02313883?
This trial is sponsored by Geistlich Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.